Sanofi reports Q1 IRFS EPS EUR 1.52 vs. EUR 0.91 last year

Business EPS was EUR 1.79, up 15.7% at CER and up 17.0% reported. Reports Q1 IRFS net sales EUR 9.9B, up 10.8% reported and up 9.7% at CER. Paul Hudson, CEO: “We had a strong start in 2025 with sales growth of 9.7%, benefiting from investments in innovation and a favorable base of comparison. Our focus on pipeline value delivered further growth for Sanofi (SNY) with sales from launches of new medicines and vaccines growing by 46.5%. We obtained approval for Qfitlia, a new treatment for patients with hemophilia, one of three potential launches this year. ALTUVIIIO is continuing to gain market share and is on track to become our next blockbuster in the full year. Business EPS was EUR 1.79, confirming the expected strong rebound in 2025 / Our redeployment of capital continued with significant progress on our share buyback program, the upcoming closing of the sale of a majority stake in Opella and the recent acquisition of a bispecific myeloid cell engager for deep B-cell depletion in immunology, strengthening our early pipeline and providing a potential treatment option in difficult-to-treat diseases like lupus. We achieved significant advances in the pipeline with six approvals. We also delivered steady progress across many new medicines in respiratory diseases and dermatology, including clinically meaningful efficacy for amlitelimab in asthma, allowing us to enter phase 3 development to create future value for patients, society, and our company. Underpinned by the growth in sales and business EPS, we confirm our 2025 guidance with the knowledge of the external environment we have today.”